What this pack is
LIALDA is the brand name in this record; mesalamine delayed-release tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
LIALDAGeneric namemesalamine delayed-release tablets
How this medicine works
LIALDA uses a pH-dependent polymer coat. The label describes breakdown at pH 6.8 or above, normally in the terminal ileum, followed by delayed and extended mesalamine release. This explains the exact product but creates no plan to split, crush, change tablet count or switch formulation.
Read source: United States ↗Current regulatory record · reviewed 2026-09-05More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- LIALDA
- Source-scoped market brand names
- LIALDA · United StatesCurrent regulator record ↗Current brand label; a regulatory record does not prove live stock, price or individual suitability.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- mesalamine delayed-release tablets
- Dosage-form class
- LIALDA is a mesalamine delayed-release tablet whose coat begins to break down at about pH 6.8 or above, followed by extended release. ASACOL HD, PENTASA, APRISO, DELZICOL, suppositories, enemas and products from different manufacturers are separate exact products and cannot be self-interchanged by a shared ingredient or total milligrams.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed brand label (SPL v49; 24 March 2026)
Mesalamine 1.2 g per tablet; 120-tablet bottle
- Product code
- NDC 54092-476-12
- Form and route
- LIALDA mesalamine delayed-release tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-05; actual marketing, stock and availability are not established.
- mesalamine
- 1.2 glabelled amount per tablet; not an individual's tablet count, frequency, course or conversion to another mesalamine product
- Package
- 120 tablets per bottle
- Labelled appearance
- red-brown · ellipsoidal tablet · imprint S476The cited label says not to split or crush it
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
LIALDA enlarged label: per-tablet amount, swallowing whole, kidney function and interactions
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 1.2 g figure is mesalamine per tablet and 120 Tablets is the bottle count. Swallow tablets whole; do not split or crush them. Individual tablet count, frequency, course and any switch to other mesalamine products cannot be inferred from pack numbers or this page.
- Kidney function requires professional assessment before and during treatment. Prior kidney disease, older age, dehydration or concurrent nephrotoxic medicines needs extra review. Marked urine change, swelling or severe illness needs prompt care; do not self-stop or switch.
- NSAIDs and other nephrotoxic medicines may increase renal adverse-reaction risk. Do not merely separate them using a webpage; give prescriptions, OTC pain medicines, herbs and supplements together to a doctor or pharmacist.
- Azathioprine or 6-mercaptopurine may increase blood-dyscrasia risk and requires professional review of complete blood counts and platelets. Fever, unusual bruising, bleeding or marked fatigue cannot be self-assessed on a webpage.
- The label reports a higher incidence of blood dyscrasias in people aged 65 and older. Kidney change and polypharmacy are also common; review actual packs, prescriptions and tests together rather than self-reducing by age.
- Acute intolerance syndrome, severe skin reactions, chest pain, breathing difficulty, marked worsening abdominal pain/bloody stool or another acute change requires prompt medical assessment; this page does not decide stopping or exclude emergencies.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-05
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. LIALDA mesalamine 1.2 g delayed-release tablet brand label, prescribing information and 120-tablet bottle panel (SPL v49; 24 Mar 2026) ↗Current regulatory record · reviewed 2026-09-05
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-09-05FDA Drugs@FDA: product and regulatory record for LIALDA NDA 022000 ↗Current regulatory record · reviewed 2026-09-05
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about LIALDA (mesalamine delayed-release tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
LIALDA is the brand in this record and mesalamine delayed-release tablets is the active-ingredient name. Check both with the dosage form (LIALDA is a mesalamine delayed-release tablet whose coat begins to break down at about pH 6.8 or above, followed by extended release. ASACOL HD, PENTASA, APRISO, DELZICOL, suppositories, enemas and products from different manufacturers are separate exact products and cannot be self-interchanged by a shared ingredient or total milligrams.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. LIALDA mesalamine 1.2 g delayed-release tablet brand label, prescribing information and 120-tablet bottle panel (SPL v49; 24 Mar 2026) ↗Current regulatory record · reviewed 2026-09-05
- FDA Drugs@FDA: product and regulatory record for LIALDA NDA 022000 ↗Current regulatory record · reviewed 2026-09-05
HOW IT WORKS · NOT A TREATMENT PLAN
Release design: a pH-dependent coat does not make mesalamine products interchangeable
- A shared ingredient does not mean the same release site, form, strength, excipients or label. ASACOL HD, PENTASA, APRISO, DELZICOL and rectal products require separate checks.
- If intact or partial tablet-shell material is seen, swallowing is difficult or a new pack arrives, keep the pack and ask a professional; do not crush, soak or switch form yourself.
- Disease activity, symptom change, test results and kidney function require integrated clinical review. Release design does not replace follow-up or determine an individual's tablet count, course, stopping or switching.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. LIALDA mesalamine 1.2 g delayed-release tablet brand label, prescribing information and 120-tablet bottle panel (SPL v49; 24 Mar 2026) ↗Current regulatory record · reviewed 2026-09-05
- FDA: LIALDA NDA 022000 review material documenting initial approval on 16 Jan 2007 ↗reviewed 2026-09-05
- FDA Drugs@FDA: product and regulatory record for LIALDA NDA 022000 ↗Current regulatory record · reviewed 2026-09-05
SOURCE-TRACEABLE ARCHIVE
LIALDAmesalamine delayed-release tablets
This page includes an exact current U.S. public-label package panel for LIALDA, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval of LIALDA
FDA review material records initial approval of NDA 022000 on this date; this is distinct from the label's 1987 initial U.S. approval year for mesalamine.
FDA: LIALDA NDA 022000 review material documenting initial approval on 16 Jan 2007 ↗Current DailyMed label effective
SPL v49 lists the 1.2 g delayed-release tablet, exact NDC and 120-tablet bottle.
DailyMed (NLM): current U.S. LIALDA mesalamine 1.2 g delayed-release tablet brand label, prescribing information and 120-tablet bottle panel (SPL v49; 24 Mar 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current public brand labelOne exact 120-tablet bottle is displayed; not proof of live supply.
Mainland China and other markets
Local approval, brand, reference, pack and supply not yet established market by marketNo other-market status is inferred from the U.S. NDA, NDC or pack.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Does 1.2 g mean one tablet each time?
No. 1.2 g is only the amount per tablet; tablet count, frequency and course require the exact prescription and professional review.
Can another mesalamine product be switched by total milligrams?
Do not self-switch. Release design, form, strength and labelling may differ; have a doctor or pharmacist compare both actual packs or official labels.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.